Orlucent, Inc
Developer of a handheld, point-of-care fluorescence molecular imaging system and associated reagents and software to non‑invasively detect biological activity associated with early melanoma development. The company focuses on biomarker-targeted fluorescence detection, clinical validation, regulatory approvals, and in-office diagnostic workflows for dermatology.
Industries
N/A
Nr. of Employees
small (1-50)
Orlucent, Inc
61 East Main Street, Suite B, Los Gatos, CA 95030, USA
Patents
Products
Handheld fluorescence mole evaluation system
Integrated solution combining a topical fluorescent peptide reagent, a handheld near‑infrared imager, and analysis software that reports a probability score indicating biological activity associated with early melanoma development.
Handheld fluorescence mole evaluation system
Integrated solution combining a topical fluorescent peptide reagent, a handheld near‑infrared imager, and analysis software that reports a probability score indicating biological activity associated with early melanoma development.
Services
Running and supporting global clinical studies and site evaluations of a point‑of‑care fluorescence imaging system for mole assessment.
Running and supporting global clinical studies and site evaluations of a point‑of‑care fluorescence imaging system for mole assessment.
Expertise Areas
- Point‑of‑care fluorescence diagnostics
- Clinical trial design and execution for device validation
- Biomarker‑targeted imaging diagnostics
- Topical reagent development
Key Technologies
- Near‑infrared fluorescence imaging
- Topical fluorescent peptide biotags
- Handheld optical imaging devices
- αvβ3 integrin‑targeted biomarker detection
News & Updates
Received Breakthrough Device designation for the handheld mole imaging system.
Achieved renewal of ISO 13485:2016 certification for the company's quality management system.
Received California Food and Drug Branch manufacturing license.
Proof‑of‑concept activity image featured in the cover story of a melanoma research journal.
Received Breakthrough Device designation for the handheld mole imaging system.
Achieved renewal of ISO 13485:2016 certification for the company's quality management system.
Received California Food and Drug Branch manufacturing license.
Proof‑of‑concept activity image featured in the cover story of a melanoma research journal.